» Clinical applications of postbiotics in the treatment of Helicobacter infections
» Advances in probiotics research for healthcare
10 October 2018, Bio Japan 2018, PACIFICO Yokohama.

  Video overview of the seminar sponsored by Nitto Pharma Bio Japan 2018 Postbiotics for health: Analysis and application of functional gut microbial metabolites 10 October 2018, Bio Japan 2018, PACIFICO Yokohama. Coordinator Professor Jun Ogawa, Division of Applied Life Sciences Graduate Schools Agriculture, Kyoto University Invited speakers: Professor Jun Ogawa, Division of Applied Life

Continue reading »
Industrial applications of functional fatty acids produced by gut lactic acid bacteria

Yasunori Yonejima Nitto Pharma, Kyoto Nitto Pharma supply seven strains of gut lactic acid bacteria for food materials under the NOSTER brand and retains more than 400 strains in its library. The company is pursuing open innovation ‘postbiotics’ research in the search for metabolites from gut microbes to promote scientific advances in bioactive metabolites and

Continue reading »
Analysis and applications of health-supporting gut microbial metabolisms

Jun Ogawa, Ph.D. Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University. The human gut is inhabited by a large and diverse microbiota consisting of approximately 100 trillion cells of 500 to 1000 species. Reports show that the gut microbiota affects the physiology, metabolism, and immune response of the host, and a loss

Continue reading »
LipoQuality project: Advanced lipidomics strategy to identify bioactive lipids

Makoto Arita, Ph.D. Laboratory for Metabolomics, RIKEN-IMS Graduate School of Pharmaceutical Sciences, Keio University Graduate School of Medical Life Science, Yokohama City University Makoto Arita is a principal investigator of the ‘LipoQuality’ project in JSPS Grant-in-Aid for Scientific Research on Innovative Areas, that focuses on the mechanisms in which specific molecular species of lipids, namely

Continue reading »
Role of lactic acid microbes in defense against infection: Exopolysaccharide produced by Leuconostoc mesenteroides enhances antigen-specific IgA secretion

Antigen-specific immunoglobulin A (IgA) plays a salient role in host defense against mucosal infection. We reported earlier that exopolysaccharide (EPS) produced by probiotic Leuconostoc mesenteroides strain NTM048 can enhance mucosal IgA production in mice. However, the capability of enhancing antigen-specific IgA production remains unclear. Here, Chiaki Matsuzaki of Ishikawa Prefectural University and colleagues in Japan

Continue reading »
Nitto Pharma are coauthors of a paper to be presented at BMC2018

            Leuconostoc mesenteroides NTM048 strain BMC2018: 7th Beneficial Microbes Conference Details Place: Amsterdam, Netherlands Date: 26-28 November 2018 Title Exopolysaccharide produced by Leuconostoc mesenteroides strain NTM048 enhances antigen-specific IgA secretion Authors C. Matsuzaki1, C. Takagaki1,2, Y. Higashimura3, Y. Nakashima1, K. Hosomi2, J. Kunisawa2, K. Yamamoto1, K. Hisa4 Affiliations 1 Research

Continue reading »
Nitto Pharma will exhibit at Bio Japan 2018, Pacifico Yokohama, 10-12 October 2018

Nitto Pharma will sponsor a seminar on 10 October 2018 at Bio Japan 2018. Details about the exhibition booth and seminar Place: PACIFICO Yokohama, PACIFIC Convention Plaza Yokohama, 1-1-1, Minato Mirai, Nishi-ku, Yokohama, Japan. Nitto Pharma Booth: C-29 Nitto Pharma sponsored seminar: 【S-2】NITTO PHARMACEUTICAL INDUSTRIES, LTD Theme: ”Postbiotics” for health -Analysis and application of functional

Continue reading »
NITTO PHARMA SPONSORS AAAS SCIENCE WEBINAR ON 8 AUGUST 2018

The theme of the webinar is: “The new era of postbiotics: Gut microbiome-derived lipid metabolites for health and wellness”, and the speakers are Jun Ogawa (Kyoto University), Jun Kunisawa (National Institutes of Biomedical Innovation, Health and Nutrition Osaka, Japan), and Ikuo Kimura (Tokyo University of Agriculture and Technology, Fuchu, Japan). The webinar is an excellent

Continue reading »
NOSTER is our strategic brand

The ‘NOSTER’ brand. The NOSTER brand underscores the desire of all the staff at Nitto Pharma—an innovative biopharmaceutical company based in Kyoto, Japan—to contribute to the treatment of people suffering from diseases. Nitto Pharma has continued to conduct research and development of microorganisms since 1947 in cooperation with many kinds of universities and research institutes based on

Continue reading »
Nitto Pharma headquarters is located in a leafy and spacious environment

Nitto Pharma Headquarters, Kyoto. Nitto Pharma is located in a quiet residential area about 30-minutes by train from Kyoto Station. The company is surrounded by narrow cobbled streets lined with Sakura trees and the view from the entrance of the company’s premises is one of carefully mown lawns surrounded by many varieties of flowers and

Continue reading »